Indications
Voraxaze is indicated to reduce toxic plasma methotrexate concentration in adults and children (aged 28 days and older) with delayed methotrexate elimination or at risk of methotrexate toxicity.
Composition
- Active substance
- glucarpidase
Official product information
The European public assessment report holds the summary of product characteristics and the package leaflet in every EU language.
Prognia shows this product information for reference and learning. It is not treatment advice and can lag behind the official text. Always check the current product information and local protocols before prescribing.
At a glance
- Medicine
- Voraxaze
- Active substance
- glucarpidase
- ATC code
- V03AF09
- Group
- Various
- Therapeutic area
- Metabolic Side Effects of Drugs and Substances
- Marketing authorisation holder
- SERB SAS
- Status
- Authorised
- EU authorisation
- 11 Jan 2022